EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

TMEM100 acts as a TAK1 receptor that prevents pathological cardiac hypertrophy progression

Bin-Bin Zhang, Yi-Lin Zhao, Yan-Yu Lu, Ji-Hong Shen, Hui-Yong Li, Han-Xue Zhang, Xiao-Yue Yu, Wen-Cai Zhang, Gang Li, Zhan-Ying Han, Sen Guo, Xu-Tao Zhang

Cell Communication and Signaling · 2024

DOI: 10.1186/s12964-024-01816-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Communication and Signaling, 2024. Verfasst von Bin-Bin Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China. Hauptthemen laut MEDLINE: Cardiomegaly, Membrane Proteins, Myocytes, Cardiac, MAP Kinase Kinase Kinases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathological cardiac hypertrophy is the primary cause of heart failure, yet its underlying mechanisms remain incompletely understood. Transmembrane protein 100 (TMEM100) plays a role in various disorders, such as nervous system disease, pain and tumorigenesis, but its function in pathological cardiac hypertrophy is still unknown. In this study, we observed that TMEM100 is upregulated in cardiac hypertrophy. Functional investigations have shown that adeno-associated virus 9 (AAV9) mediated-TMEM100 overexpression mice attenuates transverse aortic constriction (TAC)-induced cardiac hypertrophy, including cardiomyocyte enlargement, cardiac fibrosis, and impaired heart structure and function. We subsequently demonstrated that adenoviral TMEM100 (AdTMEM100) mitigates phenylephrine (PE)-induced cardiomyocyte hypertrophy and downregulates the expression of cardiac hypertrophic markers in vitro, whereas TMEM100 knockdown exacerbates cardiomyocyte hypertrophy. The RNA sequences of the AdTMEM100 group and control group revealed that TMEM100 was involved in oxidative stress and the MAPK signaling pathway after PE stimulation. Mechanistically, we revealed that the transmembrane domain of TMEM100 (amino acids 53-75 and 85-107) directly interacts with the C-terminal region of TAK1 (amino acids 1-300) and inhibits the phosphorylation of TAK1 and its downstream molecules JNK and p38. TAK1-binding-defective TMEM100 failed to inhibit the activation of the TAK1-JNK/p38 pathway. Finally, the application of a TAK1 inhibitor (iTAK1) revealed that TAK1 is necessary for TMEM100-mediated cardiac hypertrophy. In summary, TMEM100 protects against pathological cardiac hypertrophy through the TAK1-JNK/p38 pathway and may serve as a promising target for the treatment of cardiac hypertrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiomegalyMembrane ProteinsMyocytes, CardiacMAP Kinase Kinase KinasesAnimalsMiceMice, Inbred C57BLMaleDisease ProgressionHumansPhenylephrineMAP Kinase Signaling SystemOxidative StressMAP Kinase Kinase Kinase 7

Stichwörter der Autor:innen

Cardiac hypertrophyCardiomyocyte hypertrophyProtein–protein interactionTAK1TMEM100

Substanzen

Membrane ProteinsMAP Kinase Kinase KinasesPhenylephrineMAP Kinase Kinase Kinase 7

Autor:innen und Institutionen

  • Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China.
  • Department of Cardiology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
  • Department of Electrocardiogram, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Institute of Chronic Non-Communicable Diseases, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, China.
  • Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China. hzy91@163.com.
  • Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, No.1 Jianshe East Road, Zhengzhou, China. fccguos@edu.zzu.com.

Zitieren

APA

Zhang, B. B., Zhao, Y. L., Lu, Y. Y., Shen, J. H., Li, H. Y., Zhang, H. X., Yu, X. Y., Zhang, W. C., Li, G., Han, Z. Y., Guo, S., & Zhang, X. T. (2024). TMEM100 acts as a TAK1 receptor that prevents pathological cardiac hypertrophy progression. Cell Communication and Signaling. https://doi.org/10.1186/s12964-024-01816-2

Vancouver

Zhang BB, Zhao YL, Lu YY, Shen JH, Li HY, Zhang HX, et al. TMEM100 acts as a TAK1 receptor that prevents pathological cardiac hypertrophy progression. Cell Communication and Signaling. 2024. doi:10.1186/s12964-024-01816-2

BibTeX
@article{Zhang2024,
  author = {Zhang, Bin-Bin and Zhao, Yi-Lin and Lu, Yan-Yu and Shen, Ji-Hong and Li, Hui-Yong and Zhang, Han-Xue and Yu, Xiao-Yue and Zhang, Wen-Cai and Li, Gang and Han, Zhan-Ying and Guo, Sen and Zhang, Xu-Tao},
  title = {TMEM100 acts as a TAK1 receptor that prevents pathological cardiac hypertrophy progression},
  journal = {Cell Communication and Signaling},
  year = {2024},
  doi = {10.1186/s12964-024-01816-2}
}
Kostenlos starten →